Since its invention in 1983, genomics laboratories across the globe have been utilizing the polymerase chain reaction (PCR) to amplify DNA. Since then, few fundamentally new technologies have been invented in this area. In order to “democratize” the field of genomics, Cardea Bio has developed the CRISPR-SNP-Chip, a system that enables the detection of many biomolecules directly, using a minimally processed sample.

Technology Networks spoke with Cardea Bio’s CEO, Michael Heltzen, and Dr. Kiana Aran, PhD, chief scientific officer, to find out more about the development of the SNP-Chip and how it has been used in a recent study to detect sickle cell disease and amyotrophic lateral sclerosis (ALS).

Read the full article here:

This post was originally published at Cardea Bio was acquired by Paragraf on 2 May 2023.

Join our mailing list